InvestmentApr 30, 2026, 06:42 AM
COAG Files S-1/A for IPO of 15M Shares; Targets $16.00-$18.00/Share
AI Summary
Hemab Therapeutics Holdings, Inc. filed an S-1/A for its initial public offering, proposing to sell 15,000,000 shares of common stock at an estimated price range of $16.00 to $18.00 per share. The offering is expected to generate approximately $231.4 million in net proceeds, which will fund the clinical development of its lead assets, sutacimig and HMB-002, for various blood coagulation disorders. The company is a clinical-stage biotechnology firm focused on therapies for serious bleeding and thrombotic diseases, with two assets in Phase 1/2 and Phase 2 clinical development, despite incurring significant losses and identifying material weaknesses in internal controls.
Key Highlights
- Initial public offering of 15,000,000 common shares.
- Estimated IPO price range of $16.00 to $18.00 per share.
- Expected net proceeds of approximately $231.4 million from the offering.
- Sutacimig Phase 1/2 showed 19-87% reduction in ATBR for Glanzmann thrombasthenia.
- HMB-002 Phase 1/2 showed >1.5-fold increase in VWF and Factor VIII levels.
- Net loss of $(63.9) million in 2025, up from $(48.7) million in 2024.
- R&D expenses increased to $59.6 million in 2025 from $41.4 million in 2024.
- Pro forma cash, cash equivalents, and marketable securities of $416.9 million.